NATCO Pharma FY26 Annual Report: Rs 43,759 Mn Revenue, Rs 14,185 Mn PAT

Revenue declinedResults View source PDF Explain this filing

NATCOPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹828.00

prior close

₹829.00

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.0%+1.5% vs market

Pharmaceuticals peers, median of 174sector+0.2%+1.3% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Smallcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.2

15m

+0.6

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.0+1.5+0.2+1.3

Next day

-0.4+0.2-0.6+0.5-0.9

-0.3-0.3-0.0+0.2-0.5

-1.1-0.3-0.9+0.4-1.5

-1.4-0.8-0.6-0.4-1.0

-1.4-3.2+1.7-1.9+0.4

-1.1-2.6+1.5-1.1+0.0

15d

+1.8-4.0+5.7-0.1+1.8

-2.1-3.0+1.0-0.7-1.4

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

NATCO Pharma filed its FY26 Annual Report ahead of the 43rd AGM on September 30, 2026. Revenue stood at Rs 43,759 Mn with PAT of Rs 14,185 Mn (after associate share) and EBITDA of Rs 17,341 Mn. Key highlights: acquired 35.75% stake in South Africa's Adcock Ingram (later raised to 49%), launched generic Semaglutide and Risdiplam in India, and announced demerger of Crop Health Sciences. Group revenue crossed $1 billion.

Likely market impact

Strong PAT of Rs 14,185 Mn and South Africa acquisition support growth, though export formulations face near-term decline from Lenalidomide exclusivity loss.